Triclofos Sodium for Pediatric Sedation in Non-Painful Neurodiagnostic Studies
ConclusionTFS, when administered in a controlled and monitored environment, may be safe for use in children, including those with underlying neurocognitive disorders. (Source: Pediatric Drugs)
Source: Pediatric Drugs - July 10, 2019 Category: Pediatrics Source Type: research
Botulinum Toxin in the Management of Children with Cerebral Palsy
AbstractDuring the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used medical intervention in children with cerebral palsy. In this review we consider the gaps in our knowledge in the use of BoNT-A and reasons why muscle morphology and function in children with cerebral palsy are impaired. We rev iew limitations in our knowledge regarding the mechanisms underlying the development of contractures and the difficulty in preventing them. It is clear from this review that injection of BoNT-A in the large muscles of both the upper and lower limbs of children with cerebral palsy will result in a pr e...
Source: Pediatric Drugs - June 30, 2019 Category: Pediatrics Source Type: research
Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients & lt; 16 Years with Epilepsy: An Open-Label Trial
ConclusionsThis open-label trial in pediatric patients with epilepsy provides preliminary information that short-term, adjunctive brivaracetam treatment is well tolerated and effective. Plasma concentrations of brivaracetam and metabolites increased with increasing dose. (Source: Pediatric Drugs)
Source: Pediatric Drugs - June 27, 2019 Category: Pediatrics Source Type: research
Current and Emerging Agents for the Treatment of Hypoglycemia in Patients with Congenital Hyperinsulinism
AbstractCongenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycmia in neonatles and children. The inappropriate secretion of insulin by the pancreatic β-cells produces recurrent hypoglycemia, which can lead to severe and permanent brain damage. CHI results from mutations in different genes that play a role in the insulin secretion pathway, and each differs in their responsiveness to medical treatment. Currently, the only available approved treatm ent for hyperinsulinism is diazoxide. Patients unresponsive to diazoxide may benefit from specialized evaluation including genetic testing and 18F-DOPA P...
Source: Pediatric Drugs - June 19, 2019 Category: Pediatrics Source Type: research
Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital
ConclusionThe current vancomycin dosing strategy is ineffective in achieving therapeutic trough levels in children admitted to the ICU. Sub-therapeutic vancomycin trough levels significantly increase the risk of mortality. (Source: Pediatric Drugs)
Source: Pediatric Drugs - June 19, 2019 Category: Pediatrics Source Type: research
